SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd

BlackBerry is trending as community members discuss its potential, citing bullish technical indicators and increased volume.  Optimism surrounds potential partnerships and the value of QNX technology in automotive AI, with some speculating on a possible acquisition.  The community anticipates upcoming earnings as a catalyst for further upward movement.

Pump.fun

$PUMP.X is trending as discussions revolve around its potential as a platform and its association with meme coins on Solana. The community is actively discussing its growth potential, with some anticipating significant gains. There's also excitement around live streams and community engagement.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as the community rallies around the meme-driven coin built on Solana, asking 'What's Updog?' and highlighting its presence on the Jupiter Strict List. Some are drawing comparisons to other popular dog-themed cryptocurrencies, while others are focused on loading up and pushing for new highs. The community emphasizes its long-term development and charitable aspects.

Orderly Network is a L2 built on OP stack delivering a permissionless liquidity layer for Web3 trading, with one shared orderbook across different blockchains — powered by Orderly Chain and LayerZero. Our mission is to empower trading on any chain, any asset, any interface. Orderly offers spot and perpetual futures orderbooks trading across Arbitrum, Optimism, Polygon, Base ,Mantle and Near, while expanding to other blockchains.

Orderly Network

Orderly Network's crypto, $ORDER.X, is gaining attention, sparking community excitement about its potential. The community is actively discussing its prospects alongside other cryptocurrencies, speculating on potential growth. Some users are indicating they are accumulating the token.

Uranus DEX is an innovative decentralized exchange (DEX) built on the Solana blockchain, designed as a permissionless, player-versus-player (PvP) prediction market platform. Unlike traditional DEXs that rely on automated market makers (AMMs) or liquidity pools, Uranus DEX offers a unique model where users can make long or short predictions on the price movements of any Solana-based token, including real-world assets (RWAs). This community-driven platform enables traders to engage directly from their crypto wallets, creating a transparent and accessible trading experience.  Built on Solana’s high-throughput, low-cost blockchain, Uranus DEX delivers fast transactions with minimal fees, appealing to both novice and seasoned traders. Its permissionless design allows users to speculate on any listed Solana token without restrictions, fostering a competitive PvP environment for price predictions. This flexibility empowers users to engage in dynamic trading battles, making it a standout in the decentralized finance (DeFi) space.  The native token, $URA, is integral to the ecosystem, supporting staking, governance, and community rewards. Trading fees are used to buy and vault $URA tokens, which are then allocated to liquidity events, ensuring platform sustainability and incentivizing participation. Uranus DEX enhances user accessibility by integrating with social platforms like X, allowing seamless trading through intuitive interfaces, broadening its appeal and engagement.  The platform has gained traction in the crypto community, notably through its participation in the Bonk Hackathon and milestones like reaching 1,000 followers on X. Positioned as a first mover in PvP prediction markets, Uranus DEX aims to democratize DeFi with a scalable, user-centric approach. Its smart contracts are verifiable on Solana’s blockchain explorer, ensuring transparency and security for users.  As with any DeFi platform, users should exercise caution, verify contract addresses, and be aware of risks such as price slippage and market volatility. For more details, visit uranus.today to explore the platform’s features, tokenomics, and community initiatives. Uranus DEX redefines decentralized trading by combining Solana’s technical efficiency with a bold vision for accessible, community-driven prediction markets.

Ura is trending amid discussions about its constructive chart patterns, potential gap fill toward all-time highs, and alignment with the AI energy thesis. Bullish community members are pointing to strong closes and increasing volume, anticipating further upward movement if futures behave favorably. Mentions of Trump are also appearing alongside the trending stock.

MATH is a one stop crypto solution platform which contains MathWallet, MATH VPOS Pool, MathDEX, MATH dApp Store, MATH Staking, MATH Pay, MATH Chain, etc.

MATH

MATH.X is trending as traders discuss recent price movement and potential for future pumps, with some highlighting its low market cap and past performance. Community members are debating whether it can sustain gains or if it will be another pump and dump, while others express frustration with its price action and CEO.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending as the community debates potential price movements and trading strategies, with some anticipating a decline and others hoping for a breakout. Discussions revolve around identifying 'suckers' and 'greedy' traders, reflecting a speculative environment. Recent integrations like the tokenized uranium offering (xU3O8) and Ankr's Etherlink RPC are also mentioned, highlighting ongoing development within the Tezos ecosystem.

Flora Growth Corp. engages in the production of organic cannabis and pharmaceutical-grade medical products. It operates through the following segments: House of Brands and Commercial and Wholesale. The House of Brands segment includes multiple categories including food and beverage, nutraceuticals, cannabis accessories and technology, personal care and wellness. The Commercial and Wholesale segment includes distribution of pharmaceutical products to international markets. The company was founded on March 13, 2019 and is headquartered in Fort Lauderdale, FL.

Flora Growth Corp

FLGC is trending due to community excitement surrounding potential catalysts, including a new supply agreement and participation in German cannabis pilot programs. Conversations revolve around the company's strategy, such as its expansion into the THC-infused beverage market and integration of crypto payments, while some express concerns about dilution and past performance. The stock's low float and potential for a short squeeze are also key talking points among investors.

Anheuser-Busch InBev SA/NV operates as a holding company, which engages in the manufacture and distribution of alcoholic and non-alcoholic beverages. It operates through the following geographical segments: North America, Middle Americas, South America, EMEA, Asia Pacific, and Global Export and Holding Companies. The company was founded on August 2, 1977 and is headquartered in Leuven, Belgium.

Anheuser-Busch InBev SA/NV - ADR

Anheuser-Busch InBev

Anheuser-Busch InBev (BUD) is trending as community members discuss potential short squeeze opportunities and debate the effectiveness and impact of past boycotts on the company's stock. Some are speculating about potential marketing strategies, including celebrity endorsements, to revive the Bud Light brand, while others are analyzing recent earnings reports and volume declines in key markets.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending as community members highlight its recent price surge and compare it to other decentralized exchanges like $HYPE.X and $MYX.X.  Discussions revolve around potential price targets and whether it will continue its parabolic run or experience a pullback. Many are attributing the attention to backing from major players like Peter Thiel and Pantera Capital.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Analysts delivered mixed verdicts on Eli Lilly after the drugmaker released late-stage trial results for its investigational oral weight-loss drug Orforglipron, sending shares sharply lower on Thursday.<a href="https://stocktwits.com/symbol/LLY">Eli Lilly shares</a> closed down 14.1% at $640.86 on Thursday,&nbsp;their worst session since Aug. 9, 2000,&nbsp;but climbed in after-hours trading. The stock is now at lows last seen in early 2024.Leerink downgraded Eli Lilly to ‘Market Perform’ from ‘Outperform’ and cut its price target to $715 from $944, calling the results “disappointing” and lowering its long-term projections.&nbsp;The firm stated that its investment thesis had&nbsp;shifted and no longer&nbsp;anticipated upward pressure on consensus estimates, warning of rising GLP-1 competition by the end of the decade, even as rival Novo Nordisk faces pricing pressure.BofA, by contrast, called Eli Lilly’s second quarter (Q2) earnings and FY25 guidance raise “refreshing” compared with Novo’s “troubled” quarter, saying the drop in Lilly’s stock was “way overdone” and created a buying opportunity.&nbsp;The bank kept its ‘Buy’ rating and $1,000 price target, saying Eli Lilly remains “in pole position in obesity.”The Phase 3 ATTAIN-1 trial in 3,127 adults with obesity or overweight showed patients on the highest 36 mg dose l<a href="https://stocktwits.com/news-articles/markets/equity/nifty-sensex-recover-to-end-in-green-august-7/chrmRMkRddF">ost an average of 12.4% of body weight</a>, or 27.3 pounds, at 72 weeks, with nearly 60% losing at least 10%.&nbsp;Lilly stated that safety was consistent with injectable GLP-1 drugs, such as Mounjaro. The company plans to seek regulatory approval by the end of the year.H.C. Wainwright’s Joseph Pantginis said Viking Therapeutics’ VK2735 “remains a standout” after comparing discontinuation rates favorably with Eli Lilly’s data. The firm reiterated its ‘Buy’ rating on Viking with a $102 target and raised its target for Structure Therapeutics to $75 from $60, citing the potential of its oral GLP-1 candidate aleniglipron.Eli Lilly also lifted its 2025 revenue guidance midpoint by $1.5 billion to $60 billion–$62 billion and now expects adjusted EPS of $21.75–$23.The company’s Q2 revenue jumped 38% to $15.56 billion, with $5.2 billion from Mounjaro and $3.38 billion from Zepbound. Adjusted EPS was $6.31, topping forecasts.On Stocktwits, retail sentiment for Eli Lilly, which was among the top three trending tickers, was ‘extremely bullish’ amid a 1,228% surge in 24-message volume.One user on Stocktwits said they believed Eli Lilly shares would rebound eventually, but not immediately, noting that with Friday approaching and the rest of the world yet to react, it might be better to wait before adding more calls or shares.<stembedurl>https://stocktwits.com/SIbilisWhisper/message/624244609</stembedurl>Another user commented that they had bought as much stock as they could, calling it “way oversold” despite what they viewed as an extremely bullish earnings report, adding that stock market makers “are a mystery.”<stembedurl>https://stocktwits.com/Mypointofbay/message/624237111</stembedurl>Eli Lilly’s stock has declined&nbsp;about 17% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound

A late-stage study tested three doses of Eli Lilly’s oral GLP-1 drug, Orforglipron, in more than 3,100 adults, with the highest dose resulting in an average weight loss of 27.3 pounds over 72 weeks.

Equity

Pfizer Inc.'s (PFE) decision to halt the development of its oral GLP-1 candidate due to a potential liver toxicity issue could pose tailwinds for smaller biotech rivals, according to Wall Street analysts.According to The Fly, JPMorgan thinks Pfizer's scrapping of its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pfizer-ends-development-of-weight-loss-pill-danuglipron/chfCPelRba2">danuglipron</a> program opens the door for Structure Therapeutics’ (GPCR)GSBR-1290 (aleniglipron) to become the second small molecule oral GLP-1 to reach the market.It also makes Viking Therapeutics' (VKTX) an "even more attractive partnership candidate," the analyst said.Meanwhile, BTIG also flagged Viking as a key beneficiary, reiterating its 'Buy' rating and $125 price target, implying a 400% upside from the last close.&nbsp;The research firm pointed to Viking's "competitive" oral candidate VK2735, currently in Phase 2 trials, with data expected in the second half of 2025.&nbsp;A Phase 3 study for the injectable form is also set to begin in the second quarter.Media reports suggest Pfizer could now look to external assets. BTIG said it remains focused on Viking's "compelling pipeline and data" regardless of Pfizer's next steps.Retail sentiment for Viking Therapeutics turned 'bullish' late Monday from 'bearish' a day ago, accompanied by an 8,220% surge in message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/VKTX_sentiment_and_message_volume_on_April_14_png_16bef741c1.webp" alt="VKTX sentiment and message volume on April 14.png" width="1318" height="316"><figcaption>VKTX sentiment and message volume on April 14. | source: Stocktwits</figcaption></figure>One user thought Viking's stock "should be up 30-40%" as it has the "best in class oral GLP-1 now."<stembedurl>https://stocktwits.com/rxptgh/message/611544179</stembedurl>Another watcher speculated that Pfizer could likely buy Viking Therapeutics following the news.<stembedurl>https://stocktwits.com/KnysnaNow/message/611596706</stembedurl>Structure Therapeutics, meanwhile, saw its sentiment meter jump into 'extremely bullish' levels from 'bearish' a day ago.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/GPCR_sentiment_and_message_volume_on_April_14_png_6c34839d3e.webp" alt="GPCR sentiment and message volume on April 14.png" width="1318" height="316"><figcaption>GPCR sentiment and message volume on April 14. | source: Stocktwits</figcaption></figure>A bullish user said the company's aleniglipron "is going to be best in class" among GLP-1 oral pills, and CEO Ray Stevens "knows it's an easy winner and big money."<stembedurl>https://stocktwits.com/DAR2487/message/611630051</stembedurl>Structure's stock is down over 30% year to date, while Viking's has lost nearly 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

One user thought Viking's stock "should be up 30-40%" as it has the "best in class oral GLP-1 now."

Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish

Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates.

 Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For Viking, Structure Therapeutics

Structure CEO on the competitive landscape for oral GLP-1 drugs

Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings...

Promising Outlook for Structure Therapeutics with Strong Pipeline and Financial Stability

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR Research Report) today and s...

Buy Rating Backed by Strategic Partnership Opportunities and Strong Patent Portfolio for Structure Therapeutics

Leerink Partners analyst David Risinger has reiterated their bullish stance on GPCR stock, giving a Buy rating on July 22. David Risinger has given...

Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?

Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest...

Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics...

Peering Into Structure Therapeutics's Recent Short Interest

Structure Therapeutics CEO on GLP drugs

Structure Therapeutics CEO on GLP drugs...

Ozempic competitors, psychedelic stocks, and Moderna after COVID: Pharma news roundup

Zealand Pharma and Structure Therapeutics both announced new clinical trial results for their experimental weight loss drugs. The stock of several psychedelic medicines companies fell on Wednesday...

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in February 2019 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

GPCR
Structure Therapeutics Inc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GPCR News

GPCR Structure Therapeutics Inc - ADR